Jeti Peripheral Thrombectomy System
Walk Vascular
FDA Clearance Information
The JETi Peripheral Thrombectomy System was cleared by the FDA through the 510(k) pathway on December 9, 2019. It is manufactured by Walk Vascular and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Percutaneous removal of thrombus from peripheral arteries.
- Treatment of arterial occlusions in the peripheral vasculature.
- Mechanical fragmentation and aspiration of thrombotic material to help restore blood flow.
Clinical Applications
- Percutaneous thrombectomy for acute limb ischemia caused by arterial thrombus.
- Removal of thrombus from occluded lower-extremity arteries.
- Treatment of selected peripheral arterial occlusions when rapid clot removal is needed.
- Catheter-based thrombus aspiration during an endovascular revascularization procedure.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The system is used through percutaneous vascular access, commonly from the common femoral artery, with fluoroscopic guidance.
- Available catheter sizes and required sheath or guidewire compatibility depend on the specific JETi system configuration; operators should follow the current instructions for use.
- It is intended for peripheral arterial use and should not be assumed to be cleared for coronary, cerebral, venous, or dialysis-access thrombectomy unless specifically stated in the applicable labeling.
- Potential complications include bleeding or hematoma at the access site, arterial dissection or perforation, distal embolization, vessel spasm, contrast reaction, kidney injury, and recurrent thrombosis.
- MRI safety depends on the individual device components and labeling. The system should be removed before MRI unless the current instructions for use identify the relevant components as MR Conditional.
Frequently Asked Questions
What are the clinical indications for JETi Peripheral Thrombectomy System?
The JETi system is indicated for the treatment of arterial occlusions, particularly in cases of acute limb ischemia.
What outcomes have been reported in clinical studies?
Studies report the device's effectiveness in thrombus fragmentation and aspiration, though detailed outcomes are limited.
What complications have been reported?
Reported complications include limited data on adverse events, with further research needed to establish a comprehensive safety profile.